Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes

• Published in: Scientific reports Vol. 12; no. 1; p. 7658
• Main Authors: Lindenberg, Melanie A., Retèl, Valesca P., van der Poel, Henk G., Bandstra, Ferdau, Wijburg, Carl, van Harten, Wim H.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10-05-2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4025/1752; 692/4028/546; 692/700/3934; Cancer surgery; Costs; Hospitals; Humanities and Social Sciences; Laparoscopy; multidisciplinary; Population studies; Prostate cancer; Prostatectomy; Robotic surgery; Science; Science (multidisciplinary); Urological surgery
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-10746-3

Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands showing significantly improved long-term urinary functioning after RARP compared to Laparoscopic RP (LRP), we evaluated the cost-effectiveness of RARP compared to LRP. A decision tree was constructed to measure the costs and effects from a Dutch societal perspective over a ~ 7 year time-horizon. The input was based on the aforementioned study, including patient-reported consumption of addition care and consumed care for ergonomic issues reported by surgeons. Intervention costs were calculated using a bottom-up costing analysis in 5 hospitals. Finally, a probabilistic-, one-way sensitivity- and scenario analyses were performed to show possible decision uncertainty. The intervention costs were €9964 for RARP and €7253 for LRP. Total trajectory costs were €12,078 for RARP and €10,049 for LRP. RARP showed higher QALYs compared to LRP (6.17 vs 6.11). The incremental cost-utility ratio (ICUR) was €34,206 per QALY gained, in favour of RARP. As a best-case scenario, when RARP is being centralized (> 150 cases/year), total trajectory costs decreased to €10,377 having a higher utilization, and a shorter procedure time and length of stay resulting in an ICUR of €3495 per QALY gained. RARP showed to be cost-effective compared to LRP based on data from a population-based, large scale study with 7 years of follow-up. This is a clear incentive to fully reimburse RARP, especially when hospitals provide RARP centralized.